Por favor, use este identificador para citar o enlazar este ítem:
http://repositoriodigital.ipn.mx/handle/123456789/12564
Título : | Estudio Aleatorizado, Multicéntrico, para Comparar la Eficacia y Seguridad del Fumarato De Quetiapina de Liberación Prolongada como Monoterapia o en Combinación con Litio en el Tratamiento de Pacientes Con Depresión Bipolar Aguda |
Autor : | Dr. Asbun Bojalil, Juan M. en C. López Canales, Jorge Skiold Q. F. B. RODRÍGUEZ GARCÍA, JESÚS ENRIQUE |
Palabras clave : | Fumarato De Quetiapina Monoterapia Litio Depresión Bipolar Aguda |
Fecha de publicación : | 14-ene-2011 |
Resumen : | Objective: The main purpose of this work is to demonstrate that Quetiapine used in monotherapy once daily is not inferior to the combination of Quetiapine once daily with Lithium twice a day. Method: 88 patients, male and female, 18 to 65 years old, with a diagnostic of Bipolar disorder I or II by DSM-IV, with at least one recent and confirmed mayor depression episode, shorter than year but longer than two weeks. Patients were randomized in two treatment branches Quetiapina (50 mg o 100 mg o 200 mg o 300 mg) or combined treatment of Quetiapine with Lithium twice a day (300 mg/day to 1800 mg/day). The primary efficacy measure was mean change from baseline to week 8 in the Montgomery-Åsberg Depression Rating Scale total score. Additional efficacy assessments included the Hamilton Depression Rating Scale. Results: Both treatments demonstrated an improvement in the total score for MADRS and HAM-D scales. It´s demonstrated statistically, through the t-student, that the improvement in patients condition treated with Quetiapine monotherapy is not inferior to the improvement observed with the combine therapy with lithium twice a day. Conclusions: The monotherapy with Quetiapine is not inferior to the therapy of Quetiapina combined with Lithium in the treatment of Mayor Depression |
Descripción : | Objective: The main purpose of this work is to demonstrate that Quetiapine used in monotherapy once daily is not inferior to the combination of Quetiapine once daily with Lithium twice a day. Method: 88 patients, male and female, 18 to 65 years old, with a diagnostic of Bipolar disorder I or II by DSM-IV, with at least one recent and confirmed mayor depression episode, shorter than year but longer than two weeks. Patients were randomized in two treatment branches Quetiapina (50 mg o 100 mg o 200 mg o 300 mg) or combined treatment of Quetiapine with Lithium twice a day (300 mg/day to 1800 mg/day). The primary efficacy measure was mean change from baseline to week 8 in the Montgomery-Åsberg Depression Rating Scale total score. Additional efficacy assessments included the Hamilton Depression Rating Scale. Results: Both treatments demonstrated an improvement in the total score for MADRS and HAM-D scales. It´s demonstrated statistically, through the t-student, that the improvement in patients condition treated with Quetiapine monotherapy is not inferior to the improvement observed with the combine therapy with lithium twice a day. Conclusions: The monotherapy with Quetiapine is not inferior to the therapy of Quetiapina combined with Lithium in the treatment of Mayor Depression |
URI : | http://www.repositoriodigital.ipn.mx/handle/123456789/12564 |
Aparece en las colecciones: | Mediateca |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Tesis Jesus Rodriguez.pdf | Estudio Aleatorizado, Multicéntrico, para Comparar la Eficacia y Seguridad del Fumarato De Quetiapina de Liberación Prolongada como Monoterapia o en Combinación con Litio en el Tratamiento de Pacientes Con Depresión Bipolar Aguda | 1.16 MB | Adobe PDF | Visualizar/Abrir |
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.